9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Financial Results, Press Release
Announces Pricing of Public Offering of Ordinary Shares and Pre-Funded Warrants
Crescent Biopharma Reports $171.6 Million in Cash as of June 30, 2026
Crescent Biopharma, Inc. Annual Meeting Vote Results - June 2, 2026
Reports First Quarter 2026 Financial Results and Recent Business Highlights
Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights
Crescent Biopharma Partners with Kelun-Biotech, Raises $185M for Therapeutics, Investor Presentation
Reports Third Quarter 2025 Financial Results and Recent Business Highlights
Q2
Amended Quarterly Report
Q1
FY 2024
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Post-Effective Amendment to Registration Statement
Correspondence
Submission Upload